Blue Earth Therapeutics News
These media releases are intended for business/trade media.
09, June, 2023
08, November, 2022
Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-resistant Prostate Cancer (mCRPC)
14, June, 2022
Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer